Hypertonic Saline May Aid Kids with Cystic Fibrosis Breathe Better

Babies with cystic fibrosis breathe better by inhaling hypertonic saline as inhaling it reduces the mucous plugging that can lead to airway obstruction and frequent infections.

Infants with cystic fibrosis (CF) may breathe better by inhaling hypertonic saline, reports a new study. The findings of the study are published in the American Journal of Respiratory and Critical Care Medicine.

In "Preventive Inhalation of Hypertonic Saline in Infants with Cystic Fibrosis (PRESIS): A Randomized, Double-blind, Controlled Study," Mirjam Stahl, MD, and co-authors describe a study of 40 young infants (average age three months at enrollment) with CF.

Cystic Fibrosis - Symptoms, Causes, Diagnosis, Treatment, Support Groups
Cystic fibrosis is a genetic disease involving the mucus and sweat glands and the medical world has still to find its cure

‘Lung disease is an essential factor for morbidity and mortality in patients with cystic fibrosis. Hence, prevention or delay of the onset of CF lung disease may be a promising therapeutic strategy.’
Read More..

The babies were randomly assigned to receive either hypertonic saline (saline with a 6 percent salt concentration) or isotonic (.9 percent) saline. They were followed for 12 months.

Previous studies in mice found that the salt content of hypertonic saline decreased mucous plugging that can lead to airway obstruction and repeated infections. Other studies found hypertonic saline benefited older infants and children with CF.

"Several studies from teams worldwide investigating infants and preschool children with CF identified by newborn screening revealed that CF lung disease starts in the first months of life, leaving only a narrow window of opportunity for preventive, therapeutic interventions," said Dr. Stahl, the lead study author and a pediatric pulmonologist at the Cystic Fibrosis Centre and the Translational Lung Research Center at the University of Heidelberg.

Cystic Fibrosis Patients With Specific Mutations To Benefit From New Drug
A new combination drug for cystic fibrosis has been approved by the USFDA in people ages 12 and older that can treat the underlying cause of the disease.

"Because lung disease is the most important factor for morbidity and mortality in patients with CF, prevention, or at least delay, of the onset and progression of CF lung disease may be a promising therapeutic strategy."

The researchers also tested whether lung clearance index and chest magnetic resonance imaging (MRI) could be safely performed on the infants and serve as quantitative outcome measures.

Simple Noninvasive Test can Help Personalize Cystic Fibrosis Treatment
Personalized medications can now be developed by a simple non invasive test for cystic fibrosis found a new study

Lung clearance index measures how well air is flowing through the lungs. Mucous obstruction of the smallest airways is one of the earliest features of CF lung disease, and lung clearance index can detect these changes in breathing. MRI can detect early abnormalities in lung structure.

The authors report that both procedures could be safely performed in the infants and were well tolerated, though lung clearance index in this particular study provided a better yardstick to measure the benefits of this treatment.

Cystic Fibrosis-Possible Treatment Target Identified
In cystic fibrosis, the compact mucin protein that keeps mucus too thick and sticky, causing constant lung problems is the patients.

After one year, the infants who received the hypertonic saline had a better lung clearance index. Furthermore, they gained significantly more weight (500 grams or 1.1 pounds higher mean weight after one year of treatment) and height (1.5 centimeters or just under an inch higher mean height after one year of treatment). The weight gain confirmed previous studies of hypertonic saline in a mouse model for CF lung disease. Pulmonary exacerbation rates and adverse events between the treatment groups were similar.

Study limitations include the fact that isotonic saline (sodium chloride concentration: .9 percent) is not a true placebo because it may, itself, have therapeutic benefits. The authors added that the infants were followed for only one year, so whether hypertonic saline therapy is beneficial over the long term is unknown.

The study is believed to be the first randomized controlled trial in infants with CF.

"We demonstrated that early studies are feasible in this challenging age group using innovative, sensitive outcome parameters such as lung clearance index," Dr. Stahl said. "Treatment with hypertonic saline in infants with CF is safe from diagnosis onwards, and our results suggest this preventive therapy benefits lung function and improves thriving."

Source-Eurekalert